Advertisement

Topics

Finn-Medi Research Company Profile

06:26 EDT 23rd June 2018 | BioPortfolio

Finn-Medi Research was established in 1995 and it is owned by Finnvera, the Hospital District of Pirkanmaa, the Finnish National Fund for Research and Development (SITRA), Finnish Red Cross, City of Tampere, Tampere University of Technology Foundation, and Tampere University Foundation. The company has 14 permanent employees and its projects involve more than 100 people annually. Finn-Medi Research implements some 100 projects per year. Our Turnover in 2004 was 2,4 M€. With its skilled staff and through its wide national and international connections to research institutions, financiers, corporations and other development companies, FinnMedi can offer a covering network and appropriate expertise to its customers' service

Location

Biokatu 12, 4 th floor
Tampere
33520
Finland

Contact

Phone: 358 3 3116 4023
Fax: 358 3 3116 4029
Email: info@finnmedi.fi


News Articles [41 Associated News Articles listed on BioPortfolio]

Ruder Finn Appoints Ryan Donovan to Head San Francisco Office

The move expedites the scaling of Ruder Finn's West Coast operations which have more than doubled in revenue growth over the past year, with a Read more...

Finn Benned Hansen discusses Novo Nordisk’s focus on finding novel compounds and new delivery methods

In this episode of PharmaTelevision News Review, Fintan Walton talks to Dr Finn Benned Hansen, Corporate VP Strategy and Sourcing, Novo Nordisk.

HIV-prevention drug use rises, but is still slow among non-white patients

A report by the California HIV/AIDS Policy Research Centers found the number of PrEP users in Medi-Cal increased from 79 in 2012 to 3,295 in 2016. But the authors also discovered that the use of the

Beleave (CSE: BE; OTCQX: BLEVF) to Acquire Medi-Green #Cannabis Clinic Network

TORONTO - May 1, 2018 (Investorideas.com Newswire) Beleave Inc. ("Beleave" or the "Company") (CSE: BE; OTCQX: BLEVF) is pleased to announce that it has entered into a definitive agreement to purchase ...

MEDI+SIGN And MVDconnect Announce Dealer Agreement

MVDconnect signs a dealer agreement with MEDI+SIGN to assist hospitals in raising HCAHPS scores, patient satisfaction and patient safety. SMITHSBURG, Md. (PRWEB) January 16, 2018 MEDI+SIGN, a healthc...

Steve Lieber joins MEDI+SIGN Advisory Board

MEDI+SIGN is honored to announce Steve Lieber as Advisory Board member to assist in the company’s healthcare communications and technology endeavors. SMITHSBURG, Md. (PRWEB) January 09, 2018 MEDI+S...

Boca Terry Introduces the Medi-Robe, a Revolution in Healthcare Apparel

The global bathrobe supplier’s latest innovation includes snaps on both sleeves for ease and flexibility Boca Terry, a global manufacturer and distributor of price-competiti...

International society partners with spine stakeholders on scoliosis study

The Scoliosis Research Society and the International Spine Study Group Foundation, Zimmer Biomet, Medtronic, K2M, Globus Medi -More- 

Drugs and Medications [132 Associated Drugs and Medications listed on BioPortfolio]

Denti-care denti-rinse [AR Medicom Inc]

Denti-Care Denti-Rinse 2 % Neutral Sodium Fluoride Oral Rinse Berry

Denti-care denti-rinse [AR Medicom Inc]

Denti-Care Denti-Rinse 2 % Neutral Sodium Fluoride Oral Rinse Mint

Denti-care denti-freeze [AR Medicom Inc]

Denti-Care Denti-Freeze Topical Anesthetic Gel Strawberry

Denti-care denti-freeze [AR Medicom Inc]

Denti-Care Denti-Freeze Topical Anesthetic Gel Raspberry

Mckesson medi-pak sterile [McKesson Medical-Surgical]

Drug Facts

PubMed Articles [629 Associated PubMed Articles listed on BioPortfolio]

Morphology-adaptive total variation for the reconstruction of quantitative susceptibility map from the magnetic resonance imaging phase.

Quantitative susceptibility mapping (QSM) is a magnetic resonance imaging technique that quantifies the magnetic susceptibility distribution within biological tissues. QSM calculates the underlying ma...

Quantitative susceptibility mapping using deep neural network: QSMnet.

Deep neural networks have demonstrated promising potential for the field of medical image reconstruction, successfully generating high quality images for CT, PET and MRI. In this work, an MRI reconstr...

Optimal schedule for assessing home BP variability: the Finn-Home study.

Current guidelines make no recommendations on the optimal timing or number of measurements for assessing home blood pressure variability (HBPV). Our aim was to elucidate the optimal schedule for measu...

Research matters: Meta-spin cycles, the blindness of bias, and rebuilding trust.

Meta-research is research about research. Meta-research may not be as click-worthy as a meta-pug-a pug dog dressed up in a pug costume-but it is crucial to understanding research. A particularly valua...

A consensus statement on how to conduct inclusive health research.

The active involvement of people with intellectual disabilities in research, or inclusive research, is relatively common. However, inclusive health research is less common, even though it is expected ...

Clinical Trials [1105 Associated Clinical Trials listed on BioPortfolio]

A Study of the Safety and Tolerability of MEDI-570 (Experimental Drug) in Systemic Lupus Erythematosus

The purpose of this study is to evaluate the safety and tolerability of MEDI-570 in adult subjects with moderately to severely active systemic lupus erythematosus (SLE).

Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)

The primary objective of this study is to evaluate the safety and tolerability of intravenously administered MEDI-545 compared with placebo, over a dose escalation range of 0.3-30 mg/kg, i...

Study of MEDI 507 in the Treatment of Pediatric Patients

To assess the safety of escalating dose levels of MEDI-507 in pediatric stem cell and bone marrow allograft recipients who have at least Grade II GvHD.

A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis

To compare disease activity, as measured by PASI score, of three MEDI-507 dosing (injection)regimens vs. placebo.

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528

A Phase I studyto evaluate the safety and tolerability of escalating subcutaneous (SC) doses of MEDI-528 in to healthy adult volunteers.

Companies [1045 Associated Companies listed on BioPortfolio]

Finn-Medi Research

Finn-Medi Research was established in 1995 and it is owned by Finnvera, the Hospital District of Pirkanmaa, the Finnish National Fund for Research and Development (SITRA), Finnish Red Cross, City of T...

Histola Oy Ltd

Histola Ltd is established to provide a comprehensive range of histological techniques to meet each investigators needs. Our team is offering decades of combined experience in all phases of histopatho...

Medi-Span

Medi-Span is the leading provider of drug information for thousands of health care professionals worldwide. With more than 30 years experience, Medi-Span continues to offer author...

Joseph F. Finn, Jr., C.P.A.

Finn, Warnke & Gayton

More Information about "Finn-Medi Research" on BioPortfolio

We have published hundreds of Finn-Medi Research news stories on BioPortfolio along with dozens of Finn-Medi Research Clinical Trials and PubMed Articles about Finn-Medi Research for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Finn-Medi Research Companies in our database. You can also find out about relevant Finn-Medi Research Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record